CTD and eCTD
CTD and eCTD
Student of online Professional degree in pharmaceutical regulatory affairs (PDPRA), James Lind
Institute, India
The objective of this paper is to outline CTD, eCTD and their various modules
On May 5, 2015, the U.S. Food & Drug Administration published a final, binding guidance
document requiring certain submissions in electronic (eCTD) format within 24 months. The
projected date for mandatory electronic submissions is May 5, 2017 for New Drug Applications
(NDAs), Biologic License Applications (BLAs), Abbreviated New Drug Applications (ANDAs)
and Drug Master Files (DMFs)4.
The E.U. and its European Medicines Agency began accepting eCTD submissions in
2003.However, in February 2015, the "EMA announced it would no longer accept paper
application forms for products applying to the centralized procedure beginning 1 July 2015."The
EMA verified on that date that it would no longer accept "human and veterinary centralized
procedure applications" and that all electronic application forms would have to be eCTD by
January 20165.
CTD and eCTD
Module 1 of the CTD describes the administrative information and prescribing information (for
example, the application form, the proposed product information and labelling). Module 1 is not
strictly included in the CTD since it contains documents that are specific to each region, e.g.
application forms or the proposed label7.
There are seven sections in Module 2 that should be maintained in the following order8:
2.1 Table of contents
2.2 Introduction
2.3 Quality Overall Summary
2.4 Non-clinical Overview
2.5 Clinical Overview
2.6 Non-clinical Written and Tabulated Summaries
2.7 Clinical Summary
Module 3: Quality
Chemistry, Manufacturing, and Controls reports for the product are included in Module 3 of the
registration dossier. Sections on both drug substance and drug product are included in this
module. The main headings in this section (that must not be altered) are as follows:
3.1 Table of contents of Module 3
3.2 Body of data
3.2.S Drug Substance
3.2. P+ Drug Product
3.3 Literature references used in Module 3
Non-clinical reports included in Module 4 of the dossier. The main headings in this section (that
must not be altered) are as follows8:
4.1 Table of contents of Module 4
4.2 Study reports
4.2.1 Pharmacology
4.2.2 Pharmacokinetics
4.2.3 Toxicology
4.3 Literature references used in Module 4
CTD and eCTD
Clinical reports included in Module 5 of the dossier. The main headings in this section (that
must not be altered) are as follows8:
5.1 Table of contents of Module 5
5.2 Tabular listing of all clinical studies
5.3 Clinical study reports
5.3.1 Reports of biopharmaceutic studies
5.3.2 Reports of studies pertinent to pharmacokinetics using human biomaterials
5.3.3 Reports of human pharmacokinetic (PK) studies
5.3.4 Reports of human pharmacodynamic (PD) studies
5.3.5 Reports of efficacy and safety studies
5.3.6 Reports of post-marketing experience
5.3.7 Case report forms and individual patient listings
5.4 Literature references.
For quick referencing of information, the XML backbone allows agencies to automatically
upload the sequence into their systems and hyper-linking. Since all files are submitted
electronically there is no need for agencies to scan documents or industry to print, transport and
CTD and eCTD
store masses of paper. Changes and updates to the dossier are easy for reviewers to identify, and,
with electronic submission portals, can be presented to the authorities within minutes of
completion, drastically reducing processing time10.
References:
1. "Guidance for Industry, ICH M4: Organization of the CTD" U.S. Department of Health and Human
Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for
Biologics Evaluation and Research (CBER) August 2001
2. CTD AND ECTD. (n.d.). Retrieved from
http://www.authorstream.com/Presentation/manohar.kasturi-1570061-ctd-ectd/
3. Common Technical Document. (2019, August 14). Retrieved from
https://en.wikipedia.org/wiki/Common_Technical_Document
4. Guidance for Industry: Providing Regulatory Submissions in Electronic Format—Human
Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications.
(2006). Biotechnology Law Report, 25(1), 35-45. doi:10.1089/blr.2006.25.35
5. “Electronic Application Forms Mandatory for EU Centralized Procedure.” Regulatory Affairs
Professionals Society (RAPS), www.raps.org/regulatory-focus%E2%84%A2/news-
articles/2015/7/electronic-application-forms-mandatory-for-eu-centralized-procedure.
6. “CTD.” ICH, www.ich.org/products/ctd.html.
7. Jordan, Debbie. “An Overview of the Common Technical Document (CTD) Regulatory
Dossier.” Medical Writing, vol. 23, no. 2, 2014, pp. 101–105.,
doi:10.1179/2047480614z.000000000207.
8. Australian Government Department of Health. “CTD Module 1.” Therapeutic Goods
Administration (TGA), Australian Government Department of Health, 10 July 2019,
www.tga.gov.au/ctd-module-1.
9. “Electronic Common Technical Document.” Wikipedia, Wikimedia Foundation, 7 Jan. 2019,
en.wikipedia.org/wiki/Electronic_common_technical_document.
10. “What Is Regulatory Affairs?” Trac Services, www.tracservices.co.uk/what-is-regulatory-
affairs/.